Company
Orthocell Limited
ASX:OCC
Orthocell makes collagen-based implantable devices and autologous cell therapies for repairing tissue that degrades or fails to heal with age: peripheral nerve, tendon, bone and cartilage. Three commercial products: Remplir, a collagen wrap used in peripheral nerve repair surgery; Striate+, a collagen membrane for dental bone regeneration; and OrthoACI, an autologous chondrocyte implantation therapy for cartilage defects. Remplir is the commercial driver, cleared for sale in 45 US states with distribution also in Canada and Australia. The longevity relevance is demand-side rather than mechanistic: this is surgical tissue repair for an older population, not an intervention targeting biological ageing itself. Revenue is real but small (A$13.2m in FY2026), and US unit volumes remain modest (119 devices in the June 2026 quarter).
At a glance
- Listing
- ASX:OCC
- Category
- Regenerative medicine
- Headquarters
- Murdoch, Perth, Western Australia, Australia
- Market cap
- Approximately A$205m to A$236m (July 2026; A$236.03m at the 15 April 2026 close of A$1.06, around A$204.84m at a later close of A$0.76)
Thesis
Why it is in this universe
- Category
- Regenerative medicine
- Market
- Australia
- Recent inflection
- 12 July 2026: Orthocell reported record FY2026 revenue of A$13.2m, up 44% year on year, with a record June quarter of A$3.8m. US Remplir distribution now reaches roughly 50% of the US population, hospital purchasing accounts rose 27% to 70, surgeon adoption rose 55% to 76, and the company secured approval across US Department of Defence and Veterans Affairs networks, opening access to 221 military and veterans medical centres. Source: Proactive Investors, 12 July 2026.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:OCC |
| Secondary listing | OTC: ORHHF |
| Market cap | Approximately A$205m to A$236m (July 2026; A$236.03m at the 15 April 2026 close of A$1.06, around A$204.84m at a later close of A$0.76) |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Murdoch, Perth, Western Australia, Australia
- Website
- stockhead.com.au
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
12 July 2026: Orthocell reported record FY2026 revenue of A$13.2m, up 44% year on year, with a record June quarter of A$3.8m. US Remplir distribution now reaches roughly 50% of the US population, hospital purchasing accounts rose 27% to 70, surgeon adoption rose 55% to 76, and the company secured approval across US Department of Defence and Veterans Affairs networks, opening access to 221 military and veterans medical centres. Source: Proactive Investors, 12 July 2026.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Orthocell (ASX:OCC) company profile · Stockhead
- Orthocell delivers record FY2026 revenue as US Remplir rollout accelerates · Proactive Investors
- Orthocell (ASX:OCC) Market Cap & Net Worth · StockAnalysis
- Orthocell (ASX:OCC) Shares Surge on Wednesday · Kalkine
Every entity profile on variis is sourced. Not investment advice.